| Originalspråk | Odefinierat/okänt |
|---|---|
| Sidor (från-till) | 926–936 |
| Tidskrift | Molecular Therapy |
| Volym | 24 |
| Nummer | 5 |
| DOI | |
| Status | Publicerad - 2016 |
| MoE-publikationstyp | A1 Tidskriftsartikel-refererad |
Finansiering
This work was supported by the Academy of Finland grants 218062 (C.S.) 260599 (E.Ö., D.D., and J.M.R.) and Sigrid Juselius Foundation and Cancer Society of Finland (C.S.). R.N. was supported by the Swedish Cultural Foundation of Finland, Svensk-österbottniska samfundet, K. Albin Johansson foundation, Liv och Hälsa Foundation. S.L. was supported by the Swedish Cultural Foundation of Finland, Magnus Ehrnrooth Foundation, Waldemar von Frenckell Foundation, K. Albin Johansson foundation, the Swedish Research Council, EU (ITN NotchIT). M.B. was supported by Ulm University funding. E.M. was supported by the Norwegian Cancer Society (grant number 732200), the Western health board of Norway (Helse Vest; grant numbers 911182 and 911789), and the Bergen Research Foundation. The Cell Imaging Core at the Turku Center of Biotechnology is thanked for access to infrastructure and technical assistance. The in vivo fluorescence imaging was performed at the Molecular Imaging Centre (MIC), University of Bergen, and Mireia Mayoral Safont is thanked for her technical assistance. The authors declare that they have no conflict of interest.
Projekt
- 1 Slutfört
-
Targeting Notch signalign in cancer
Sahlgren, C. (Ansvarig forskare)
01/01/10 → 31/07/14
Projekt: Forskning
Citera det här
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver